Enfusion (ENFN) Financials

$10.85 +0.05 (+0.45%)

Closing price 04/17/2025

Extended Trading

$10.85 0.00 (0.00%)

As of 04/17/2025 04:24 PM Eastern

Annual Income Statements for Enfusion

This table shows Enfusion's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	2.82	6.03	-7.65	-158	4.06	13
Consolidated Net Income / (Loss)	3.92	9.25	-13	-282	4.06	13
Net Income / (Loss) Continuing Operations	3.92	9.25	-13	-282	4.06	13
Total Pre-Tax Income	7.39	11	-12	-282	4.49	13
Total Operating Income	6.16	12	-12	-276	6.07	14
Total Gross Profit	137	117	103	80	58	42
Total Revenue	202	175	150	112	80	59
Operating Revenue	202	175	150	112	80	59
Total Cost of Revenue	65	58	47	32	21	17
Operating Cost of Revenue	65	58	47	32	21	17
Total Operating Expenses	131	105	115	356	52	28
Selling, General & Admin Expense	79	65	69	151	36	17
Marketing Expense	25	20	29	52	9.93	7.43
Research & Development Expense	27	20	17	153	6.32	4.15
Total Other Income / (Expense), net	1.23	-0.46	-0.23	-5.78	-1.58	-0.73
Interest & Investment Income	1.69	1.64	0.41	-4.59	-1.66	-
Other Income / (Expense), net	-0.46	-2.11	-0.64	-1.19	0.08	-0.00
Income Tax Expense	3.47	2.23	1.07	0.58	0.43	0.49
Net Income / (Loss) Attributable to Noncontrolling Interest	1.09	3.23	-5.61	-124	0.00	0.00
Basic Earnings per Share	$0.03	$0.07	($0.10)	($2.26)	$0.00	$0.00
Weighted Average Basic Shares Outstanding	92.05M	88.20M	85.39M	83.05M	0.00	0.00
Diluted Earnings per Share	$0.03	$0.07	($0.10)	($2.26)	$0.00	$0.00
Weighted Average Diluted Shares Outstanding	129.55M	129.43M	85.39M	83.05M	0.00	0.00
Weighted Average Basic & Diluted Shares Outstanding	258.00M	256.14M	230.54M	113.05M	-	-

This table shows Enfusion's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	0.12	1.42	1.83	-0.54	0.62	1.83	0.63	2.95	0.49	1.54
Consolidated Net Income / (Loss)	0.17	1.96	2.55	-0.76	0.90	2.66	1.00	4.69	0.79	2.60
Net Income / (Loss) Continuing Operations	0.17	1.96	2.55	-0.76	0.90	2.66	1.00	4.69	0.79	2.60
Total Pre-Tax Income	2.46	2.86	2.95	-0.88	2.18	3.03	1.19	5.09	1.21	2.89
Total Operating Income	1.58	2.98	2.70	-1.11	2.13	2.69	2.45	4.68	1.37	2.94
Total Gross Profit	37	35	33	32	31	30	29	28	27	27
Total Revenue	53	51	49	48	46	44	43	41	41	39
Operating Revenue	53	51	49	48	46	44	43	41	41	39
Total Cost of Revenue	16	16	16	16	16	15	14	13	13	12
Operating Cost of Revenue	16	16	16	16	16	15	14	13	13	12
Total Operating Expenses	35	32	31	33	29	27	26	23	26	24
Selling, General & Admin Expense	21	19	19	20	17	17	16	14	15	13
Marketing Expense	6.57	6.22	6.02	6.22	5.55	5.50	5.28	4.09	6.00	7.28
Research & Development Expense	7.24	6.84	6.10	6.55	6.06	4.94	4.46	4.43	4.78	3.86
Total Other Income / (Expense), net	0.87	-0.12	0.25	0.24	0.05	0.34	-1.26	0.41	-0.17	-0.06
Interest & Investment Income	0.53	0.49	0.36	0.32	0.44	0.25	0.46	0.49	-	-
Other Income / (Expense), net	0.34	-0.61	-0.11	-0.08	-0.47	0.17	-1.72	-0.08	-0.58	-0.06
Income Tax Expense	2.29	0.90	0.40	-0.12	1.28	0.37	0.19	0.40	0.42	0.29
Net Income / (Loss) Attributable to Noncontrolling Interest	0.05	0.54	0.72	-0.22	0.28	0.83	0.37	1.75	0.29	1.06
Weighted Average Basic Shares Outstanding	92.05M	92.90M	91.48M	89.51M	88.20M	87.74M	88.31M	88.86M	85.39M	85.16M
Weighted Average Diluted Shares Outstanding	129.55M	128.98M	128.85M	89.51M	129.43M	127.84M	129.86M	132.35M	85.39M	131.76M
Weighted Average Basic & Diluted Shares Outstanding	258.00M	257.14M	256.82M	256.22M	256.14M	254.96M	246.86M	232.57M	230.54M	228.11M

This table details how cash moves in and out of Enfusion's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	19	-27	-1.82	50	8.04	0.25
Net Cash From Operating Activities	35	26	14	-0.32	1.67	12
Net Cash From Continuing Operating Activities	35	26	14	-0.32	1.67	12
Net Income / (Loss) Continuing Operations	3.92	9.25	-13	-282	4.06	13
Consolidated Net Income / (Loss)	3.92	9.25	-13	-282	4.06	13
Depreciation Expense	12	9.99	6.34	3.98	2.29	1.16
Amortization Expense	0.23	0.09	0.03	0.22	0.06	0.02
Non-Cash Adjustments To Reconcile Net Income	27	16	32	292	1.01	0.27
Changes in Operating Assets and Liabilities, net	-7.87	-9.44	-11	-15	-5.76	-1.80
Net Cash From Investing Activities	-14	-9.67	-7.93	-8.01	-5.07	-4.43
Net Cash From Continuing Investing Activities	-14	-9.67	-7.93	-8.01	-5.07	-4.43
Purchase of Property, Plant & Equipment	-11	-9.67	-7.93	-8.01	-5.07	-4.43
Other Investing Activities, net	-3.00	0.00	0.00	-	-	-
Net Cash From Financing Activities	-1.40	-43	-7.96	59	12	-7.54
Net Cash From Continuing Financing Activities	-1.40	-43	-7.96	59	12	-7.54
Repayment of Debt	0.00	-1.46	0.00	-100	-2.27	-2.09
Payment of Dividends	-0.14	0.00	0.00	-3.28	-76	-35
Issuance of Common Equity	0.00	17	0.00	261	93	57
Other Financing Activities, net	-1.27	-59	-7.96	-11	-77	-57
Effect of Exchange Rate Changes	-0.51	0.18	-0.09	-0.09	-0.12	-0.09
Cash Income Taxes Paid	2.05	1.84	1.58	0.41	0.26	-

This table details how cash moves in and out of Enfusion's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	6.18	14	1.55	-2.71	3.95	3.88	-27	-7.95	-1.00	6.98
Net Cash From Operating Activities	9.67	16	7.31	1.53	6.59	12	6.02	0.92	7.52	7.84
Net Cash From Continuing Operating Activities	9.67	16	7.31	1.53	6.59	12	6.02	0.92	7.52	7.84
Net Income / (Loss) Continuing Operations	0.17	1.96	2.55	-0.76	0.90	2.66	1.00	4.69	0.79	2.60
Consolidated Net Income / (Loss)	0.17	1.96	2.55	-0.76	0.90	2.66	1.00	4.69	0.79	2.60
Depreciation Expense	3.25	2.96	2.87	2.67	3.52	2.52	2.08	1.87	1.69	1.70
Amortization Expense	0.06	0.06	0.06	0.06	0.08	0.00	0.01	0.01	0.01	0.01
Non-Cash Adjustments To Reconcile Net Income	5.88	5.60	6.55	8.63	4.98	5.38	4.50	0.87	5.87	2.51
Changes in Operating Assets and Liabilities, net	0.32	5.59	-4.71	-9.06	-2.89	1.54	-1.57	-6.52	-0.84	1.03
Net Cash From Investing Activities	-2.66	-2.78	-5.71	-2.75	-2.30	-2.61	-2.22	-2.55	-1.75	-0.92
Net Cash From Continuing Investing Activities	-2.66	-2.78	-5.71	-2.75	-2.30	-2.61	-2.22	-2.55	-1.75	-0.92
Purchase of Property, Plant & Equipment	-2.66	-2.78	-2.71	-2.75	-2.30	-2.61	-2.22	-2.55	-1.75	-0.92
Effect of Exchange Rate Changes	-0.83	0.48	-0.04	-0.12	0.24	-0.31	0.22	0.03	0.27	0.08
Cash Income Taxes Paid	1.21	0.31	0.17	0.37	1.25	0.26	0.13	0.21	0.53	0.72

This table presents Enfusion's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Total Assets	143	109	124	106	39
Total Current Assets	94	70	97	90	29
Cash & Equivalents	54	36	63	64	14
Accounts Receivable	32	28	26	18	12
Prepaid Expenses	5.34	5.01	6.11	6.03	2.79
Other Current Assets	1.71	1.17	2.30	1.06	-
Plant, Property, & Equipment, net	21	18	16	13	8.78
Total Noncurrent Assets	29	21	11	3.36	1.40
Noncurrent Note & Lease Receivables	3.00	0.00	-	-	-
Other Noncurrent Operating Assets	26	21	11	3.36	1.40
Total Liabilities & Shareholders' Equity	143	109	124	106	39
Total Liabilities	44	31	20	8.64	107
Total Current Liabilities	27	20	17	8.11	11
Accounts Payable	0.87	2.21	1.69	2.53	0.48
Accrued Expenses	20	14	12	5.58	7.67
Other Current Liabilities	6.08	4.26	4.03	0.00	-
Total Noncurrent Liabilities	16	11	2.96	0.54	96
Capital Lease Obligations	14	11	2.96	-	-
Other Noncurrent Operating Liabilities	2.15	0.00	-	0.54	0.43
Commitments & Contingencies	0.00	0.00	0.00	-	0.00
Total Equity & Noncontrolling Interests	100	77	103	97	-234
Total Preferred & Common Equity	73	54	65	55	-234
Preferred Stock	0.00	0.00	0.00	-	0.00
Total Common Equity	73	54	65	55	-234
Common Stock	244	227	244	227	-233
Retained Earnings	-170	-173	-179	-171	0.00
Accumulated Other Comprehensive Income / (Loss)	-0.73	-0.41	-0.50	-0.33	-0.21
Noncontrolling Interest	26	24	38	42	0.00

This table presents Enfusion's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	135	120	111	102	94	121	116
Total Current Assets	85	74	71	62	60	87	96
Cash & Equivalents	48	34	33	32	28	55	64
Accounts Receivable	32	34	31	25	25	24	29
Prepaid Expenses	3.58	4.48	5.42	4.08	4.97	5.60	2.61
Other Current Assets	1.39	1.57	1.68	1.46	1.72	2.09	0.89
Plant, Property, & Equipment, net	21	20	19	18	18	17	15
Total Noncurrent Assets	29	26	21	22	17	18	4.15
Noncurrent Note & Lease Receivables	3.00	3.00	-	-	-	-	-
Other Noncurrent Operating Assets	26	23	21	22	17	18	4.15
Total Liabilities & Shareholders' Equity	135	120	111	102	94	121	116
Total Liabilities	39	31	28	28	22	22	12
Total Current Liabilities	24	18	17	16	14	14	12
Accounts Payable	1.18	0.82	3.36	1.34	0.87	1.29	1.19
Accrued Expenses	16	12	9.51	11	8.13	7.40	11
Other Current Liabilities	5.94	5.19	4.53	4.40	4.76	5.01	-
Total Noncurrent Liabilities	15	13	11	12	8.05	8.64	0.44
Capital Lease Obligations	15	13	-	12	8.05	-	-
Commitments & Contingencies	0.00	0.00	0.00	-	-	-	-
Total Equity & Noncontrolling Interests	96	89	83	73	72	99	103
Total Preferred & Common Equity	70	64	58	51	48	64	61
Preferred Stock	0.00	0.00	0.00	0.00	0.00	-	-
Total Common Equity	70	64	58	51	48	64	61
Common Stock	240	236	232	225	224	240	241
Retained Earnings	-170	-172	-173	-174	-175	-176	-179
Accumulated Other Comprehensive Income / (Loss)	-0.20	-0.51	-0.48	-0.55	-0.38	-0.47	-0.67
Noncontrolling Interest	26	25	25	23	24	35	42

This table displays calculated financial ratios and metrics derived from Enfusion's official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	15.51%	16.09%	34.60%	40.39%	34.79%	0.00%
EBITDA Growth	-11.23%	419.67%	97.72%	-3,307.62%	-43.46%	0.00%
EBIT Growth	-42.13%	178.11%	95.45%	-4,600.80%	-55.60%	0.00%
NOPAT Growth	-66.12%	214.95%	95.66%	-3,618.44%	-58.90%	0.00%
Net Income Growth	-57.69%	169.77%	95.30%	-7,050.06%	-67.91%	0.00%
EPS Growth	-57.14%	170.00%	95.58%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	35.30%	81.08%	4,551.57%	-119.10%	-86.47%	0.00%
Free Cash Flow Firm Growth	-798.55%	102.22%	90.86%	-1,789.73%	0.00%	0.00%
Invested Capital Growth	11.75%	20.98%	32.60%	99.48%	0.00%	0.00%
Revenue Q/Q Growth	3.31%	3.54%	6.12%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-0.15%	16.13%	97.93%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	4.74%	9.74%	95.90%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	-25.51%	-1.05%	96.09%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-15.68%	1.23%	95.69%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	-12.50%	95.78%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	9.77%	-3.52%	1,620.05%	94.13%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	40.24%	109.77%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-5.99%	-1.22%	10.68%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	67.82%	66.97%	68.67%	71.49%	73.16%	71.27%
EBITDA Margin	8.77%	11.41%	-4.15%	-244.29%	10.69%	25.49%
Operating Margin	3.05%	6.85%	-7.96%	-246.99%	7.63%	23.50%
EBIT Margin	2.83%	5.64%	-8.38%	-248.05%	7.74%	23.49%
Profit (Net Income) Margin	1.94%	5.30%	-8.82%	-252.68%	5.10%	21.44%
Tax Burden Percent	52.98%	80.57%	108.81%	100.21%	90.36%	96.30%
Interest Burden Percent	129.72%	116.67%	96.72%	101.66%	73.00%	94.78%
Effective Tax Rate	47.02%	19.43%	0.00%	0.00%	9.64%	3.70%
Return on Invested Capital (ROIC)	5.81%	19.87%	-21.77%	-777.81%	66.21%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	3.78%	20.76%	-13.88%	-1,657.61%	62.83%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-1.38%	-9.64%	8.57%	-1,142.40%	-78.14%	0.00%
Return on Equity (ROE)	4.42%	10.23%	-13.20%	-1,920.21%	-11.94%	0.00%
Cash Return on Invested Capital (CROIC)	-5.30%	0.88%	-49.80%	-844.25%	-133.79%	0.00%
Operating Return on Assets (OROA)	4.52%	8.46%	-10.96%	-381.68%	15.74%	0.00%
Return on Assets (ROA)	3.10%	7.95%	-11.54%	-388.81%	10.39%	0.00%
Return on Common Equity (ROCE)	3.17%	6.71%	-7.91%	11,644.12%	-40.97%	0.00%
Return on Equity Simple (ROE_SIMPLE)	5.35%	17.24%	-20.40%	-510.42%	-1.74%	0.00%
Net Operating Profit after Tax (NOPAT)	3.26	9.63	-8.37	-193	5.49	13
NOPAT Margin	1.62%	5.52%	-5.57%	-172.89%	6.90%	22.63%
Net Nonoperating Expense Percent (NNEP)	2.02%	-0.89%	-7.89%	879.79%	3.37%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	2.87%	10.86%	-7.87%	-	-	-
Cost of Revenue to Revenue	32.18%	33.03%	31.33%	28.51%	26.84%	28.73%
SG&A Expenses to Revenue	39.10%	37.03%	45.74%	134.84%	45.11%	28.17%
R&D to Revenue	13.26%	11.40%	11.42%	137.33%	7.94%	7.02%
Operating Expenses to Revenue	64.77%	60.13%	76.63%	318.48%	65.52%	47.77%
Earnings before Interest and Taxes (EBIT)	5.70	9.84	-13	-277	6.16	14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	18	20	-6.23	-273	8.51	15
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	36.17	46.08	33.93	42.81	0.00	0.00
Price to Tangible Book Value (P/TBV)	36.17	46.08	33.93	42.81	0.00	0.00
Price to Revenue (P/Rev)	13.14	14.17	14.67	21.19	4.01	5.40
Price to Earnings (P/E)	938.21	410.47	0.00	0.00	78.49	25.19
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.11%	0.24%	0.00%	0.00%	1.27%	3.97%
Enterprise Value to Invested Capital (EV/IC)	44.43	46.60	49.81	70.90	34.31	0.00
Enterprise Value to Revenue (EV/Rev)	13.07	14.17	14.53	21.00	7.15	0.00
Enterprise Value to EBITDA (EV/EBITDA)	148.98	124.11	0.00	0.00	66.87	0.00
Enterprise Value to EBIT (EV/EBIT)	462.54	251.19	0.00	0.00	92.41	0.00
Enterprise Value to NOPAT (EV/NOPAT)	807.88	256.83	0.00	0.00	103.65	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	75.97	96.45	154.33	0.00	341.68	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	5,805.86	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.14	0.14	0.03	0.00	-1.45	0.00
Long-Term Debt to Equity	0.14	0.14	0.03	0.00	-1.41	0.00
Financial Leverage	-0.37	-0.46	-0.62	0.69	-1.24	0.00
Leverage Ratio	1.42	1.29	1.14	4.94	-0.57	0.00
Compound Leverage Factor	1.85	1.50	1.11	5.02	-0.42	0.00
Debt to Total Capital	12.51%	12.61%	2.78%	0.00%	322.96%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	8.19%	0.00%
Long-Term Debt to Total Capital	12.51%	12.61%	2.78%	0.00%	314.76%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	23.13%	26.86%	36.12%	43.25%	542.33%	0.00%
Common Equity to Total Capital	64.36%	60.53%	61.10%	56.75%	-765.29%	0.00%
Debt to EBITDA	0.81	0.56	-0.47	0.00	11.59	0.00
Net Debt to EBITDA	-2.28	-1.23	9.56	0.00	9.95	0.00
Long-Term Debt to EBITDA	0.81	0.56	-0.47	0.00	11.29	0.00
Debt to NOPAT	4.37	1.16	-0.35	0.00	17.96	0.00
Net Debt to NOPAT	-12.34	-2.54	7.11	0.00	15.42	0.00
Long-Term Debt to NOPAT	4.37	1.16	-0.35	0.00	17.50	0.00
Altman Z-Score	36.78	47.34	64.70	155.42	4.90	0.00
Noncontrolling Interest Sharing Ratio	28.32%	34.41%	40.11%	706.40%	-243.25%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	3.42	3.44	5.57	11.06	2.71	0.00
Quick Ratio	3.16	3.14	5.09	10.19	2.45	0.00
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2.97	0.43	-19	-210	-11	0.00
Operating Cash Flow to CapEx	318.42%	265.06%	178.49%	-3.97%	32.85%	277.85%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	17.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	10.88
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	1.60	1.50	1.31	1.54	2.04	0.00
Accounts Receivable Turnover	6.71	6.47	6.82	7.35	6.53	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	10.27	10.24	10.44	10.23	9.06	0.00
Accounts Payable Turnover	42.14	29.58	22.36	21.15	44.13	0.00
Days Sales Outstanding (DSO)	54.36	56.38	53.50	49.67	55.88	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	8.66	12.34	16.32	17.26	8.27	0.00
Cash Conversion Cycle (CCC)	45.70	44.05	37.18	32.41	47.60	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	59	53	44	33	17	0.00
Invested Capital Turnover	3.59	3.60	3.91	4.50	9.60	0.00
Increase / (Decrease) in Invested Capital	6.24	9.20	11	16	17	0.00
Enterprise Value (EV)	2,635	2,472	2,185	2,345	569	0.00
Market Capitalization	2,649	2,473	2,206	2,367	319	319
Book Value per Share	$0.28	$0.21	$0.29	$0.49	($12.46)	$0.00
Tangible Book Value per Share	$0.28	$0.21	$0.29	$0.49	($12.46)	$0.00
Total Capital	114	89	106	97	31	0.00
Total Debt	14	11	2.96	0.00	99	0.00
Total Long-Term Debt	14	11	2.96	0.00	96	0.00
Net Debt	-40	-24	-60	-64	85	0.00
Capital Expenditures (CapEx)	11	9.67	7.93	8.01	5.07	4.43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	12	14	17	17	6.82	0.00
Debt-free Net Working Capital (DFNWC)	66	50	79	82	21	0.00
Net Working Capital (NWC)	66	50	79	82	18	0.00
Net Nonoperating Expense (NNE)	-0.65	0.37	4.89	89	1.43	0.70
Net Nonoperating Obligations (NNO)	-40	-24	-60	-64	85	0.00
Total Depreciation and Amortization (D&A)	12	10	6.37	4.20	2.35	1.18
Debt-free, Cash-free Net Working Capital to Revenue	5.81%	7.99%	11.23%	15.40%	8.58%	0.00%
Debt-free Net Working Capital to Revenue	32.83%	28.39%	52.83%	73.03%	26.09%	0.00%
Net Working Capital to Revenue	32.83%	28.39%	52.83%	73.03%	22.95%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.03	$0.07	($0.10)	($2.26)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	92.05M	88.20M	85.39M	83.05M	0.00	0.00
Adjusted Diluted Earnings per Share	$0.03	$0.07	($0.10)	($2.26)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	129.55M	129.43M	85.39M	83.05M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	258.00M	256.14M	230.54M	113.05M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	3.26	9.63	-8.37	-193	5.49	13
Normalized NOPAT Margin	1.62%	5.52%	-5.57%	-172.89%	6.90%	22.63%
Pre Tax Income Margin	3.67%	6.58%	-8.11%	-252.16%	5.65%	22.26%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	19.15
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	18.45
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	13.03
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	12.33
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	3.47%	0.00%	0.00%	-1.16%	1,863.41%	276.64%
Augmented Payout Ratio	3.47%	0.00%	0.00%	-32.29%	1,863.41%	276.64%

This table displays calculated financial ratios and metrics derived from Enfusion's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.88%	15.35%	15.76%	17.28%	14.73%	13.30%	16.92%	20.01%	27.20%	34.79%
EBITDA Growth	-0.51%	0.24%	96.34%	-76.24%	111.12%	17.21%	223.16%	158.69%	100.85%	-23.41%
EBIT Growth	15.48%	-16.82%	258.01%	-125.99%	110.21%	-1.07%	118.54%	137.16%	100.27%	-41.50%
NOPAT Growth	-87.42%	-13.71%	13.46%	-118.06%	-1.72%	-10.77%	175.28%	149.83%	100.44%	-43.46%
Net Income Growth	-80.89%	-26.46%	155.21%	-116.21%	14.21%	2.42%	124.19%	137.48%	100.27%	-21.11%
EPS Growth	0.00%	0.00%	100.00%	-125.00%	0.00%	0.00%	133.33%	140.00%	100.44%	0.00%
Operating Cash Flow Growth	46.87%	33.50%	21.54%	65.91%	-12.43%	54.37%	108.24%	122.55%	229.40%	439.63%
Free Cash Flow Firm Growth	26.38%	37.60%	-78.86%	-2,309.13%	15.84%	-53.38%	84.30%	100.55%	0.00%	68.99%
Invested Capital Growth	11.75%	17.42%	29.03%	11.64%	20.98%	35.55%	21.45%	9.99%	32.60%	35.09%
Revenue Q/Q Growth	3.46%	3.46%	2.92%	3.37%	4.80%	3.83%	4.27%	1.12%	3.49%	7.15%
EBITDA Q/Q Growth	-3.02%	-2.35%	259.10%	-69.27%	-2.29%	91.25%	-56.54%	159.92%	-45.75%	300.96%
EBIT Q/Q Growth	-18.91%	-8.41%	316.90%	-184.45%	-41.59%	294.20%	-84.25%	479.82%	-72.51%	173.86%
NOPAT Q/Q Growth	-94.56%	-12.69%	399.75%	-188.43%	-62.72%	14.81%	-52.30%	381.33%	-66.15%	196.86%
Net Income Q/Q Growth	-91.21%	-23.16%	434.69%	-184.56%	-66.18%	166.63%	-78.74%	495.69%	-69.67%	162.98%
EPS Q/Q Growth	0.00%	0.00%	300.00%	0.00%	0.00%	100.00%	-75.00%	300.00%	-50.00%	166.67%
Operating Cash Flow Q/Q Growth	-40.15%	120.97%	377.10%	-76.72%	-45.60%	101.16%	551.30%	-87.71%	-4.09%	171.35%
Free Cash Flow Firm Q/Q Growth	16.29%	43.33%	-116.49%	28.32%	29.04%	-62.42%	-2,773.85%	102.73%	-29.31%	83.37%
Invested Capital Q/Q Growth	-5.99%	-6.94%	36.27%	-6.27%	-1.22%	2.27%	17.91%	1.57%	10.68%	-8.37%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.02%	68.06%	67.72%	66.34%	66.39%	67.29%	66.74%	67.53%	67.18%	69.42%
EBITDA Margin	9.88%	10.54%	11.17%	3.20%	11.31%	12.13%	6.58%	15.80%	6.15%	11.72%
Operating Margin	2.99%	5.83%	5.47%	-2.32%	4.59%	6.06%	5.73%	11.42%	3.39%	7.51%
EBIT Margin	3.64%	4.64%	5.24%	-2.49%	3.59%	6.43%	1.69%	11.22%	1.96%	7.37%
Profit (Net Income) Margin	0.32%	3.82%	5.15%	-1.58%	1.94%	6.00%	2.34%	11.46%	1.94%	6.64%
Tax Burden Percent	7.00%	68.40%	86.40%	86.67%	41.28%	87.88%	84.15%	92.22%	65.34%	90.05%
Interest Burden Percent	127.69%	120.51%	113.73%	73.47%	130.77%	106.10%	163.81%	110.70%	152.08%	100.00%
Effective Tax Rate	93.00%	31.60%	13.60%	0.00%	58.72%	12.12%	15.85%	7.78%	34.66%	9.95%
Return on Invested Capital (ROIC)	0.75%	13.32%	14.79%	-6.25%	6.83%	19.24%	16.44%	38.93%	8.65%	27.80%
ROIC Less NNEP Spread (ROIC-NNEP)	0.56%	13.63%	13.76%	-6.29%	6.78%	18.52%	19.22%	38.24%	8.82%	27.82%
Return on Net Nonoperating Assets (RNNOA)	-0.21%	-4.24%	-3.52%	3.03%	-3.15%	-8.72%	-8.52%	-21.64%	-5.44%	-23.49%
Return on Equity (ROE)	0.55%	9.08%	11.27%	-3.22%	3.68%	10.52%	7.92%	17.29%	3.20%	4.31%
Cash Return on Invested Capital (CROIC)	-5.30%	-8.53%	-17.52%	-2.01%	0.88%	-9.34%	1.54%	-0.54%	-49.80%	0.00%
Operating Return on Assets (OROA)	5.81%	7.65%	9.22%	-3.89%	5.38%	9.98%	2.71%	15.58%	2.56%	12.64%
Return on Assets (ROA)	0.52%	6.31%	9.06%	-2.47%	2.90%	9.31%	3.74%	15.90%	2.54%	11.38%
Return on Common Equity (ROCE)	0.39%	6.47%	7.83%	-2.16%	2.41%	6.67%	4.94%	10.47%	1.92%	0.59%
Return on Equity Simple (ROE_SIMPLE)	0.00%	6.64%	8.32%	6.54%	0.00%	18.02%	18.86%	6.21%	0.00%	-503.76%
Net Operating Profit after Tax (NOPAT)	0.11	2.04	2.34	-0.78	0.88	2.36	2.06	4.31	0.90	2.65
NOPAT Margin	0.21%	3.99%	4.72%	-1.62%	1.90%	5.33%	4.82%	10.53%	2.21%	6.76%
Net Nonoperating Expense Percent (NNEP)	0.19%	-0.31%	1.02%	0.04%	0.05%	0.72%	-2.78%	0.68%	-0.18%	-0.03%
Return On Investment Capital (ROIC_SIMPLE)	0.10%	-	-	-	0.99%	-	-	-	0.84%	-
Cost of Revenue to Revenue	30.98%	31.94%	32.28%	33.66%	33.61%	32.71%	33.26%	32.47%	32.82%	30.58%
SG&A Expenses to Revenue	39.95%	36.71%	37.76%	42.09%	36.82%	37.70%	38.22%	35.33%	37.20%	33.44%
R&D to Revenue	13.67%	13.37%	12.33%	13.63%	13.04%	11.13%	10.45%	10.82%	11.79%	9.87%
Operating Expenses to Revenue	66.03%	62.24%	62.26%	68.66%	61.80%	61.23%	61.02%	56.11%	63.80%	61.90%
Earnings before Interest and Taxes (EBIT)	1.93	2.37	2.59	-1.20	1.67	2.85	0.72	4.60	0.79	2.89
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	5.23	5.39	5.52	1.54	5.26	5.38	2.81	6.47	2.49	4.59
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	36.17	34.86	33.95	40.81	46.08	43.65	54.22	38.00	33.93	45.65
Price to Tangible Book Value (P/TBV)	36.17	34.86	33.95	40.81	46.08	43.65	54.22	38.00	33.93	45.65
Price to Revenue (P/Rev)	13.14	12.49	11.59	13.05	14.17	13.14	15.97	15.40	14.67	19.70
Price to Earnings (P/E)	938.21	733.00	584.00	932.43	410.47	375.56	465.39	947.07	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.11%	0.14%	0.17%	0.11%	0.24%	0.27%	0.21%	0.11%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	44.43	38.53	32.26	47.47	46.60	41.28	49.77	53.91	49.81	69.88
Enterprise Value to Revenue (EV/Rev)	13.07	12.45	11.61	13.00	14.17	13.15	16.00	15.28	14.53	19.54
Enterprise Value to EBITDA (EV/EBITDA)	148.98	137.22	123.54	157.52	124.11	129.25	159.72	213.13	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	462.54	446.92	369.46	582.96	251.19	247.22	290.43	549.56	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	807.88	555.14	464.07	557.01	256.83	227.90	260.97	629.79	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	75.97	76.92	79.40	89.97	96.45	83.45	117.19	125.23	154.33	3,364.62
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	5,805.86	0.00	3,537.81	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.16	0.14	0.00	0.14	0.17	0.11	0.00	0.03	0.00
Long-Term Debt to Equity	0.14	0.16	0.14	0.00	0.14	0.17	0.11	0.00	0.03	0.00
Financial Leverage	-0.37	-0.31	-0.26	-0.48	-0.46	-0.47	-0.44	-0.57	-0.62	-0.84
Leverage Ratio	1.42	1.40	1.32	1.28	1.29	1.23	1.19	1.16	1.14	0.37
Compound Leverage Factor	1.82	1.68	1.51	0.94	1.68	1.31	1.94	1.28	1.74	0.37
Debt to Total Capital	12.51%	13.64%	12.53%	0.00%	12.61%	14.16%	10.03%	0.00%	2.78%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	12.51%	13.64%	12.53%	0.00%	12.61%	14.16%	10.03%	0.00%	2.78%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	23.13%	23.57%	24.57%	29.74%	26.86%	26.41%	30.03%	35.75%	36.12%	40.75%
Common Equity to Total Capital	64.36%	62.78%	62.91%	70.26%	60.53%	59.43%	59.94%	64.25%	61.10%	59.25%
Debt to EBITDA	0.81	0.86	0.72	0.00	0.56	0.70	0.49	0.00	-0.47	0.00
Net Debt to EBITDA	-2.28	-1.87	-1.22	0.00	-1.23	-1.14	-1.20	0.00	9.56	0.00
Long-Term Debt to EBITDA	0.81	0.86	0.72	0.00	0.56	0.70	0.49	0.00	-0.47	0.00
Debt to NOPAT	4.37	3.47	2.72	0.00	1.16	1.24	0.80	0.00	-0.35	0.00
Net Debt to NOPAT	-12.34	-7.56	-4.59	0.00	-2.54	-2.01	-1.97	0.00	7.11	0.00
Long-Term Debt to NOPAT	4.37	3.47	2.72	0.00	1.16	1.24	0.80	0.00	-0.35	0.00
Altman Z-Score	36.69	38.01	42.90	50.16	47.10	46.58	71.52	65.10	65.05	134.69
Noncontrolling Interest Sharing Ratio	28.32%	28.80%	30.45%	33.02%	34.41%	36.60%	37.66%	39.46%	40.11%	86.26%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.42	3.62	4.15	4.07	3.44	3.79	4.33	6.32	5.57	8.01
Quick Ratio	3.16	3.41	3.81	3.67	3.14	3.45	3.85	5.76	5.09	7.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.13	-7.32	-13	-5.96	-8.32	-12	-7.22	0.27	-9.89	-7.64
Operating Cash Flow to CapEx	363.24%	582.41%	270.29%	55.79%	286.97%	464.37%	271.20%	36.24%	430.76%	850.54%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-150.32	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	155.21	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	121.78	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.60	1.65	1.76	1.56	1.50	1.55	1.60	1.39	1.31	1.72
Accounts Receivable Turnover	6.71	6.84	6.40	6.57	6.47	6.26	6.06	6.58	6.82	5.90
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	10.27	10.10	10.13	10.17	10.24	10.05	9.72	9.85	10.44	10.15
Accounts Payable Turnover	42.14	50.95	73.95	26.00	29.58	43.79	60.42	39.87	22.36	25.17
Days Sales Outstanding (DSO)	54.36	53.33	57.01	55.56	56.38	58.30	60.26	55.46	53.50	61.82
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	8.66	7.16	4.94	14.04	12.34	8.33	6.04	9.15	16.32	14.50
Cash Conversion Cycle (CCC)	45.70	46.17	52.08	41.52	44.05	49.96	54.22	46.31	37.18	47.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	59	63	68	50	53	54	53	45	44	40
Invested Capital Turnover	3.59	3.34	3.13	3.85	3.60	3.61	3.41	3.70	3.91	4.11
Increase / (Decrease) in Invested Capital	6.24	9.36	15	5.19	9.20	14	9.28	4.05	11	10
Enterprise Value (EV)	2,635	2,430	2,186	2,361	2,472	2,217	2,614	2,402	2,185	2,769
Market Capitalization	2,649	2,437	2,183	2,369	2,473	2,214	2,609	2,421	2,206	2,791
Book Value per Share	$0.28	$0.27	$0.25	$0.23	$0.21	$0.21	$0.21	$0.28	$0.29	$0.27
Tangible Book Value per Share	$0.28	$0.27	$0.25	$0.23	$0.21	$0.21	$0.21	$0.28	$0.29	$0.27
Total Capital	114	111	102	83	89	85	80	99	106	103
Total Debt	14	15	13	0.00	11	12	8.05	0.00	2.96	0.00
Total Long-Term Debt	14	15	13	0.00	11	12	8.05	0.00	2.96	0.00
Net Debt	-40	-33	-22	-33	-24	-20	-20	-55	-60	-64
Capital Expenditures (CapEx)	2.66	2.78	2.71	2.75	2.30	2.61	2.22	2.55	1.75	0.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)	12	14	22	21	14	14	18	18	17	20
Debt-free Net Working Capital (DFNWC)	66	62	56	54	50	46	46	73	79	84
Net Working Capital (NWC)	66	62	56	54	50	46	46	73	79	84
Net Nonoperating Expense (NNE)	-0.06	0.08	-0.21	-0.02	-0.02	-0.30	1.06	-0.38	0.11	0.05
Net Nonoperating Obligations (NNO)	-40	-33	-22	-33	-24	-20	-20	-55	-60	-64
Total Depreciation and Amortization (D&A)	3.31	3.02	2.93	2.73	3.59	2.53	2.09	1.87	1.70	1.71
Debt-free, Cash-free Net Working Capital to Revenue	5.81%	6.95%	11.60%	11.36%	7.99%	8.32%	11.08%	11.67%	11.23%	14.47%
Debt-free Net Working Capital to Revenue	32.83%	31.70%	29.89%	29.47%	28.39%	27.09%	28.08%	46.41%	52.83%	59.31%
Net Working Capital to Revenue	32.83%	31.70%	29.89%	29.47%	28.39%	27.09%	28.08%	46.41%	52.83%	59.31%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.02	$0.02	($0.01)	$0.00	$0.02	$0.01	$0.04	$0.01	$0.02
Adjusted Weighted Average Basic Shares Outstanding	92.05M	92.90M	91.48M	89.51M	88.20M	87.74M	88.31M	88.86M	85.39M	85.16M
Adjusted Diluted Earnings per Share	$0.00	$0.02	$0.02	($0.01)	$0.00	$0.02	$0.01	$0.04	$0.01	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	129.55M	128.98M	128.85M	89.51M	129.43M	127.84M	129.86M	132.35M	85.39M	131.76M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	258.00M	257.14M	256.82M	256.22M	256.14M	254.96M	246.86M	232.57M	230.54M	228.11M
Normalized Net Operating Profit after Tax (NOPAT)	1.11	2.04	2.34	-0.78	1.49	2.36	2.06	4.31	0.90	2.65
Normalized NOPAT Margin	2.09%	3.99%	4.72%	-1.62%	3.21%	5.33%	4.82%	10.53%	2.21%	6.76%
Pre Tax Income Margin	4.64%	5.59%	5.96%	-1.83%	4.69%	6.83%	2.78%	12.42%	2.98%	7.37%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	36.59	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	30.30	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	3.17	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-3.13	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	3.47%	2.93%	2.54%	2.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	3.47%	2.93%	2.54%	2.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Enfusion's Financials

When does Enfusion's fiscal year end?

According to the most recent income statement we have on file, Enfusion's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Enfusion's net income changed over the last 5 years?

Enfusion's net income appears to be on a downward trend, with a most recent value of $3.92 million in 2024, falling from $12.66 million in 2019. The previous period was $9.25 million in 2023. See Enfusion's forecast for analyst expectations on what’s next for the company.

What is Enfusion's operating income?

Enfusion's total operating income in 2024 was $6.16 million, based on the following breakdown:

Total Gross Profit: $136.74 million
Total Operating Expenses: $130.58 million

How has Enfusion revenue changed over the last 5 years?

Over the last 5 years, Enfusion's total revenue changed from $59.03 million in 2019 to $201.61 million in 2024, a change of 241.6%.

How much debt does Enfusion have?

Enfusion's total liabilities were at $43.72 million at the end of 2024, a 38.8% increase from 2023, and a 59.2% decrease since 2020.

How much cash does Enfusion have?

In the past 4 years, Enfusion's cash and equivalents has ranged from $13.94 million in 2020 to $64.37 million in 2021, and is currently $54.48 million as of their latest financial filing in 2024.

How has Enfusion's book value per share changed over the last 5 years?

Over the last 5 years, Enfusion's book value per share changed from 0.00 in 2019 to 0.28 in 2024, a change of 28.5%.

Related Companies

This page (NYSE:ENFN) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enfusion (ENFN) Financials

Frequently Asked Questions About Enfusion's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enfusion (ENFN) Financials

Annual Income Statements for Enfusion

Quarterly Income Statements for Enfusion

Annual Cash Flow Statements for Enfusion

Quarterly Cash Flow Statements for Enfusion

Annual Balance Sheets for Enfusion

Quarterly Balance Sheets for Enfusion

Annual Metrics And Ratios for Enfusion

Quarterly Metrics And Ratios for Enfusion

Frequently Asked Questions About Enfusion's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools